Immunocore Ltd raises US$130m in Series B round

TCR specialist Immunocore Ltd US$130m Series B financing round was led by General Atlantic, with CCB International, JDRF T1D Fund, Rock Springs Capital, Terra Magnum Capital Partners and WuXi AppTec’s Corporate Venture Fund  as new co-investors. Futhermore, five existing shareholders in the company, including Eli Lilly & Company and RTW Investments participated, as well as the Bill & Melinda Gates Foundation through conversion of its outstanding loan note. 

The proceeds will enable Immunocore to expand and accelerate its growing clinical stage pipeline of ImmTAX™(Immune mobilising monoclonal TCRs Against Cancer, Infectious and Autoimmune Diseases) molecules that includes three oncology programs in MAGE-A4 (in collaboration with Genentech), NYESO-1 (in collaboration with GSK), and the lead program tebentafusp (IMCgp100), which is in pivotal clinical studies as a potential treatment for patients with metastatic uveal melanoma.

The proceeds will allow the company to stategically advance two wholly owned clinical-stage internal programs for chronic hepatitis B and for PRAME, a target expressed in a wide range of tumours. This investment is also expected to accelerate Immunocore’s novel platform to treat autoimmunity, including type one diabetes (in collaboration with the JDRF T1D Fund), advance the TCR platform and expand its database of rich and novel targets.